{"entity":{"id":"lyell-immunopharma","kind":"company","name":"Lyell Immunopharma","aka":[],"tldr":"Lyell makes next-generation CAR T-cell therapies designed to last longer in the body and resist exhaustion. Its lead product, ronde-cel, targets two proteins on lymphoma cells at once and is in pivotal trials for large B-cell lymphoma.","summary":"Lyell Immunopharma is a late-stage clinical company developing CAR T-cell therapies engineered to resist exhaustion and retain stem-like qualities. Lead candidate rondecabtagene autoleucel (ronde-cel) is an autologous dual-targeting CD19/CD20 CAR T-cell product with an OR logic gate, manufactured with a process that enriches CD62L-positive cells. It is in two pivotal trials in relapsed or refractory large B-cell lymphoma, PiNACLE (third line or later) and PiNACLE-H2H (second line); no grade 3 or higher cytokine release syndrome was seen in more than 100 patients. Pivotal data are expected mid-2027 with a BLA planned for late 2027. Ronde-cel holds RMAT and Fast Track designations. LYL273 is a CAR T candidate in a phase 1/2 trial in metastatic colorectal cancer. Lyell runs its own LyFE manufacturing centre, held about $228 million in cash at 30 June 2026 and trades on Nasdaq as LYEL.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Lyell_Immunopharma","links":[{"label":"Official website","url":"https://www.lyell.com"},{"label":"Q2 2026 results (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828026054330/lyel-20260806x8kexx991.htm"}],"tags":[],"related":[],"cancers":["dlbcl","colorectal"],"sections":["cell-therapy"],"technologies":["car-t"],"targets":["cd19","cd20"],"drugs":["rondecabtagene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05826535","nct05319314"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round sourced; the June 2021 IPO release was not located in EDGAR full-text search."],"hq":"South San Francisco, CA","country":"US","companyType":"cell-therapy","website":"https://www.lyell.com","ticker":"LYEL","stage":"public","investors":[],"funding":[]},"route":"/companies/lyell-immunopharma/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"drug":[{"id":"rondecabtagene-autoleucel","kind":"drug","name":"Rondecabtagene autoleucel","route":"/drugs/rondecabtagene-autoleucel/"}],"trial":[{"id":"nct07188558","kind":"trial","name":"A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy","route":"/trials/nct07188558/"},{"id":"nct05319314","kind":"trial","name":"LYL273 for Patients With Relapsed or Refractory mCRC","route":"/trials/nct05319314/"},{"id":"nct05826535","kind":"trial","name":"Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma","route":"/trials/nct05826535/"}]}}